Literature DB >> 33430300

Prognostic Value and Function of KLF5 in Papillary Thyroid Cancer.

Poyil Pratheeshkumar1, Abdul K Siraj1, Sasidharan Padmaja Divya1, Sandeep Kumar Parvathareddy1, Sarah Siraj1, Roxanne Diaz1, Rafia Begum1, Saif S Al-Sobhi2, Fouad Al-Dayel3, Khawla S Al-Kuraya1.   

Abstract

The Krüppel-like factor 5 (KLF5), a zinc-finger transcriptional factor, is highly expressed in several solid tumors, but its role in PTC remains unclear. We investigated the expression of KLF5 protein in a large cohort of PTC patient samples and explored its functional role and mechanism in PTC cell lines in vitro and in vivo. KLF5 overexpression was observed in 65.1% of all PTC cases and it was significantly associated with aggressive clinico-pathological parameters and poor outcome. Given the significant association between KLF5 and HIF-1α overexpression in PTC patients, we investigated the functional correlation between KLF5 and HIF-1α in PTC cells. Indeed, the analysis revealed the co-immunoprecipitation of KLF5 with HIF-1α in PTC cells. We also identified KLF5-binding sites in the HIF-1α promoter that specifically bound to KLF5 protein. Mechanistically, KLF5 promoted PTC cell growth, invasion, migration, and angiogenesis, while KLF5 downregulation via specific inhibitor or siRNA reverses its action in vitro. Importantly, the silencing of KLF5 decreases the self-renewal ability of spheroids generated from PTC cells. In addition, the depletion of KLF5 reduces PTC xenograft growth in vivo. These findings suggest KLF5 can be a possible new molecular therapeutic target for a subset of PTC.

Entities:  

Keywords:  HIF-1α; KLF5; apoptosis; invasion; papillary thyroid cancer; stemness

Year:  2021        PMID: 33430300      PMCID: PMC7825749          DOI: 10.3390/cancers13020185

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  26 in total

1.  Expression of Krűppel-like factor 5 in gastric cancer and its clinical correlation in Taiwan.

Authors:  Maw-Soan Soon; Li-Sung Hsu; Chih-Jung Chen; Pei-Yi Chu; Jia-Hung Liou; Shu-Hui Lin; Jeng-Dong Hsu; Kun-Tu Yeh
Journal:  Virchows Arch       Date:  2011-07-06       Impact factor: 4.064

2.  Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERβ and KLF5.

Authors:  Yuka Nakajima; Kensuke Akaogi; Takashi Suzuki; Asami Osakabe; Chie Yamaguchi; Nanae Sunahara; Junji Ishida; Koichiro Kako; Sonoko Ogawa; Tetsuya Fujimura; Yukio Homma; Akiyoshi Fukamizu; Akiko Murayama; Keiji Kimura; Satoshi Inoue; Junn Yanagisawa
Journal:  Sci Signal       Date:  2011-04-12       Impact factor: 8.192

3.  FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma.

Authors:  Maqbool Ahmed; Shahab Uddin; Azhar R Hussain; Aisha Alyan; Zeenath Jehan; Fouad Al-Dayel; Abdulrehman Al-Nuaim; Saif Al-Sobhi; Tarek Amin; Prashant Bavi; Khawla S Al-Kuraya
Journal:  J Clin Endocrinol Metab       Date:  2011-11-02       Impact factor: 5.958

Review 4.  Targeting Krüppel-like factor 5 (KLF5) for cancer therapy.

Authors:  Yu Gao; Ye Ding; Haiying Chen; Haijun Chen; Jia Zhou
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

5.  Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.

Authors:  Rong Bu; Abdul K Siraj; Sasidharan Padmaja Divya; Yan Kong; Sandeep Kumar Parvathareddy; Maha Al-Rasheed; Khadija A S Al-Obaisi; Ingrid G Victoria; Saif S Al-Sobhi; Mohammed Al-Dawish; Fouad Al-Dayel; Khawla S Al-Kuraya
Journal:  Int J Cancer       Date:  2017-12-29       Impact factor: 7.396

6.  KLF5 promotes hypoxia-induced survival and inhibits apoptosis in non-small cell lung cancer cells via HIF-1α.

Authors:  Xiaochen Li; Xiansheng Liu; Yongjian Xu; Jin Liu; Min Xie; Wang Ni; Shixin Chen
Journal:  Int J Oncol       Date:  2014-07-17       Impact factor: 5.650

Review 7.  Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions.

Authors:  Ji-Won Lee; Seong-Hui Bae; Joo-Won Jeong; Se-Hee Kim; Kyu-Won Kim
Journal:  Exp Mol Med       Date:  2004-02-29       Impact factor: 8.718

8.  Knockdown of KLF5 promotes cisplatin-induced cell apoptosis via regulating DNA damage checkpoint proteins in non-small cell lung cancer.

Authors:  Hao Zhang; Fei Shao; Wei Guo; Yibo Gao; Jie He
Journal:  Thorac Cancer       Date:  2019-03-21       Impact factor: 3.500

9.  Beyond proliferation: KLF5 promotes angiogenesis of bladder cancer through directly regulating VEGFA transcription.

Authors:  Yang Gao; Kaijie Wu; Yule Chen; Jiancheng Zhou; Chong Du; Qi Shi; Shan Xu; Jing Jia; Xiaoshuang Tang; Feng Li; Ke Hui; Dalin He; Peng Guo
Journal:  Oncotarget       Date:  2015-12-22

10.  KLF5 promotes the tumorigenesis and metastatic potential of thyroid cancer cells through the NF-κB signaling pathway.

Authors:  Yuehua Ma; Qingzhu Wang; Fei Liu; Xiaojun Ma; Lina Wu; Feng Guo; Shuiying Zhao; Fengjuan Huang; Guijun Qin
Journal:  Oncol Rep       Date:  2018-09-06       Impact factor: 3.906

View more
  1 in total

1.  Inhibitory effect of the novel tyrosine kinase inhibitor DCC-2036 on triple-negative breast cancer stem cells through AXL-KLF5 positive feedback loop.

Authors:  Yingying Shen; Qingyun Zhu; Maoyu Xiao; Liyang Yin; Wenjie Feng; Jianbo Feng; Jun He; Pei Li; Xiguang Chen; Wenjun Ding; Jing Zhong; Zhaolin Zeng; Zhuoye Xie; Jianghua Liu; Xuyu Zu
Journal:  Cell Death Dis       Date:  2022-08-30       Impact factor: 9.685

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.